Approval from the Swedish Medical Product Agency

Axcentua Pharmaceuticals received approval from the Swedish Medical Product Agency to initiate a phase Ib/IIa clinical trial with its lead compound AXP107-11 or genistein-SSDH for the treatment of patients with pancreatic cancer.